Compare BioNano Genomics Inc (BNGO) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Crown Castle International Corp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Crown Castle International Corp trades at $73.8 (market cap $31.33B). The key difference: Crown Castle International Corp is far larger — about 2293.6× BioNano Genomics Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CCI | |
|---|---|---|
Market Cap | $13.66M | $31.33B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $103.79 |
52-Week Low | $1.06 | $73.61 |
Enterprise Value | $16.26M | $53.69B |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Crown Castle (CCI) trades at $73.61, down 2.62% on the day and near 52-week lows. The technical picture is bearish with mixed fundamentals - strong profitability margins (73.7% gross margin) but negative shareholder equity and high debt levels. Recent Q2 2026 earnings beat expectations with AFFO of $1.13 per share, while the company transitions to a pure-play U.S. tower operator following asset sales.
The stock presents a contrarian opportunity with 50% analyst buy ratings and a $95.29 price target suggesting 29% upside, but faces significant debt burden and execution risks from strategic shifts. The 5.5% dividend yield provides income support while investors await operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
